Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Several factors including long-term eradication of the organism, cost, compliance, and adverse event profile should be considered for treating H. pylori infection in pediatric patients. Triple therapy with bismuth, tetracycline, and metronidazole is considered the gold standard for adult patients; however, tetracyclines are not recommended in children younger than 8 years due to the potential for tooth discoloration and alterations in bone growth. Dual and shorter duration of therapy should be evaluated in children with H. pylori. The new dual therapy omeprazole/clarithromycin regimens approved by the Food and Drug Administration for adults may be considered as an alternative for children when concerns include the use of salicylates or allergy to beta-lactams. Although the dosage of omeprazole in pediatric patients has not been established (no pediatric formulation exists), clarithromycin is available for use in pediatric patients. However, these drugs cannot be recommended for children with H. pylori until additional studies in this population are available. Based on the available data, aminopenicillin/bismuth or aminopenicillin/tinidazole combinations appear to be effective in eradicating H. pylori in children. Amoxicillin 50 mg/kg/d plus bismuth subsalicylate (< 10 y, 262 mg; > 10 y, 525 mg qid) or bismuth subcitrate (< 12 y, 120 mg; > 12 y, 240 mg bid) can be used for 6 weeks. The bismuth dosages represented above were those used in various studies. It should be realized, however, that a definitive dosage of bismuth subsalicylate for children in the treatment of H. pylori has not been established. The adult dosage of bismuth subsalicylate for the eradication of H. pylori is the same as that used for prophylaxis in diarrhea (525 mg qid). When dosage of this agent is unknown (particularly for the treatment of very young children), the use of established dosages for prophylaxis in diarrhea may be considered for treating H. pylori. Additionally, bismuth subsalicylate should be used with caution in children with suspected viral infections (i.e., to prevent Reye's syndrome) or those receiving concurrent therapy with interacting drugs. If available, tinidazole 20 mg/kg/d can be used with amoxicillin 50 mg/kg/d for 6 weeks to treat children infected with H. pylori.
Robinson
D M
DM
College of Pharmacy, Ohio State University, Columbus 43210, USA.
Abdel-Rahman
S M
SM
Nahata
M C
MC
D000293:Adolescent; D000658:Amoxicillin / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy; D005756:Gastritis / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D014011:Tinidazole / Q000627:therapeutic use
D006635:Histamine H2 Antagonists; D014011:Tinidazole; D000658:Amoxicillin; D001729:Bismuth